TCTMD - tctmd.com
WEBTCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
FAME 3: PCI Fails to Demonstrate Noninferiority to Surgery in …
WEBNov 4, 2021 · That set the stage for the FAME 3 study, a noninferiority trial that included 1,500 patients with three-vessel coronary artery disease randomized to CABG surgery or PCI guided by FFR. All patients had angina and/or evidence of myocardial ischemia and were amenable to either surgery or PCI as determined by the heart team.
Blood Pressure Insights in COVID-19: Watch for Drops and
WEBSep 10, 2020 · By L.A. McKeown. COVID-19 may affect hypertensive patients in a variety of ways, including being a trigger for extreme drops in blood pressure that put them at risk for acute kidney injury (AKI), according to data presented in a poster session during the virtual Hypertension 2020 Scientific Sessions. A second study from the meeting suggests ...
FDA Approves Shockwave Intravascular Lithotripsy for Calcified ...
WEBFeb 16, 2021 · FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries. Dean Kereiakes says simplicity, safety, and efficacy make the choice a no-brainer. The sticker price may raise eyebrows. (UPDATED) The US Food and Drug Administration has cleared the Shockwave intravascular lithotripsy (IVL) system for the treatment of …
Injectable Semaglutide Shortage Forces Physicians to Pivot
WEBFeb 5, 2024 · As demand for the drug continues to rise, alternatives like the oral formulation and other injectable GLP-1s come into play.
TCT 2021 | tctmd.com
WEBNov 4, 2021 · FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG. Presenter: William Fearon. Presentation TCT 2021.
TCT 2024 | tctmd.com
WEBReceive the the latest news, research, and presentations from major meetings right to your inbox.
Loading Dose Smooths Switch From Ticagrelor to Clopidogrel …
WEBMar 20, 2018 · ORLANDO, FL—Patients with coronary artery disease who need to switch from ticagrelor to clopidogrel after PCI should receive a loading dose of 600 mg clopidogrel between 12 and 24 hours following ticagrelor discontinuation, according to results from a randomized, pharmacodynamic study. Findings from the …
FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in …
WEBJul 20, 2011 · WILMINGTON, Del. - AstraZeneca announced today that the US Food and Drug Administration (FDA) has approved BRILINTA™ (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.
TCT 2022 | tctmd.com
WEBSep 16, 2022 · The PASCAL IID Registry: A Prospective Registry for Transcatheter Edge-to-Edge Repair in Prohibitive Risk Patients With Degenerative Mitral Regurgitation and Complex Mitral Valve Anatomy. Presenter: Jörg Hausleiter. Presentation TCT 2022.
Skip to content